Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Oppenheimer Holdings issued their Q3 2018 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Monday. Oppenheimer Holdings analyst D. Archila anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the quarter. Oppenheimer Holdings currently has a “Buy” rating and a $21.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.09 EPS and FY2021 earnings at $1.16 EPS.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 target price for the company in a research note on Tuesday, August 8th. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.29.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/oppenheimer-holdings-weighs-in-on-vanda-pharmaceuticals-inc-s-q3-2018-earnings-vnda.html.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 1.49% during trading on Wednesday, reaching $16.55. 91,492 shares of the company were exchanged. The company’s 50-day moving average is $17.45 and its 200 day moving average is $15.62. The firm’s market capitalization is $742.40 million. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. During the same period in the previous year, the business earned $0.01 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis.

Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its stake in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,022 shares in the last quarter. Kopp Investment Advisors LLC acquired a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $196,000. Virginia Retirement Systems ET AL acquired a new stake in Vanda Pharmaceuticals in the first quarter valued at approximately $193,000. Dynamic Technology Lab Private Ltd acquired a new stake in Vanda Pharmaceuticals in the first quarter valued at approximately $196,000. Finally, Voya Investment Management LLC boosted its stake in Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 4,605 shares in the last quarter. Institutional investors own 86.49% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.